{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-003471","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2023-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.612430+00:00","generated_at":"2026-06-20T16:00:11.209401+00:00","sec_items":["2.02","8.01","5.07","7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"VYNE shareholders approve reverse stock split; receives $5M deferred payment; redeems preferred","bullets":["Stockholders approved reverse stock split at ratio from 1:10 to 1:25; board to set effective date within one year.","Series A Preferred redeemed for $360,000 on Jan 17, 2023; Certificate of Elimination to be filed.","Received $5.0M deferred payment from Journey Medical per Asset Purchase Agreement; pro forma cash $35.9M as of Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-003471","json":"https://secwatch.observer/filing/0001104659-23-003471.json","markdown":"https://secwatch.observer/filing/0001104659-23-003471.md","text":"https://secwatch.observer/filing/0001104659-23-003471.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/0001104659-23-003471-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/tm233167d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:00:11.209401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06647315a885a7baa7b87218b639d5e037a71a6a","claim":"VYNE Therapeutics Inc. shareholders approved Adjournment Proposal at the 2023-01-12 meeting.","evidence_excerpt":"With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,029,283; votes “Against” were 3,693,414; votes abstaining or withheld were 423,246, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows: Votes For Votes Against Abstentions / Withheld 2,624,348,039 403,374,658 423,246 The Adjournment Proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/0001104659-23-003471-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-01-12"}],"fact_type":"shareholder_vote"},{"claim_id":"3030448f4ed1c7c24d8b864c3b9803447c85efd8","claim":"VYNE Therapeutics Inc. shareholders approved Reverse Stock Split Proposal at the 2023-01-12 meeting.","evidence_excerpt":"With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,230,441; votes “Against” were 3,711,239; votes abstaining or withheld were 204,263, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows: Votes For Votes Against Abstentions / Withheld 2,625,767,750 402,173,930 204,263 The Reverse Stock Split Proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/0001104659-23-003471-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-01-12"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}